Funded Tech Companies

Versartis

Headquartered in Mountain View, Versartis raised its funding from New Leaf Venture Partners, Aisling Capital and private investors.

Company Overview

Contact Information

Company Background Information

Overview

Versartis (NASDAQ: VSAR) is developing new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis has licensed the rights to three products (VRS-826, VRS-859, and VRS-317) from Amunix.

Profile

Social Media

Company News

Facebook

YouTube

Last Transaction

3/21/2014

Financing History

Management Team

Title

Name

Email & Social

Chief Executive Officer

Jay Shepard

        

Chief Financial Officer

Joshua Brumm

        

Chief Medical Officer

George Bright

        

VP - Bus. Development

Paul Westberg

        

VP - Manufacturing

Patrick Murphy

        

VP - Operations

Eric Humphriss

        

VP - Product Management

Rajendra Mohabir

        

Company Investors

• New Leaf Venture Partners (Michael Dybbs)
• Aisling Capital (Anthony Sun)
• Advent Venture Partners (Shahzad Malik)
• Sofinnova Ventures (Srinivas Akkaraju)
• Amunix
• Index Ventures (Kevin Johnson)
• New Leaf Venture Partners (Srini Akkaraju)
• Index Ventures (Roman Fleck)

Browse more funded tech companies:

Versanis Bio | Versata

Share this article

About Our Venture Capital Database

This tech company profile is powered by VentureDeal.com, a leading provider of venture capital transaction data.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary